{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:46:34Z","timestamp":1790811994262,"version":"4.1.0"},"reference-count":167,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2019,3,10]],"date-time":"2019-03-10T00:00:00Z","timestamp":1552176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2019,3,10]],"date-time":"2019-03-10T00:00:00Z","timestamp":1552176000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"name":"Dutch Society for Dermatology and Venereology"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Dermatol"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1111\/bjd.17590","type":"journal-article","created":{"date-parts":[[2018,12,26]],"date-time":"2018-12-26T10:31:02Z","timestamp":1545820262000},"page":"65-79","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":121,"title":["Interventions for rosacea based on the phenotype approach: an updated systematic review including<scp>GRADE<\/scp>assessments"],"prefix":"10.1093","volume":"181","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4780-0182","authenticated-orcid":false,"given":"E.J.","family":"Zuuren","sequence":"first","affiliation":[{"name":"Dermatology Department Leiden University Medical Centre Leiden 2333 ZA the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Fedorowicz","sequence":"additional","affiliation":[{"name":"DynaMed Plus EBSCO Health 10 Estes Street Ipswich MA 01938 U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Western Ontario London Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.M.D.","family":"Linden","sequence":"additional","affiliation":[{"name":"Department of Dermatology Amsterdam University Medical Centre Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6884-8014","authenticated-orcid":false,"given":"B.W.M.","family":"Arents","sequence":"additional","affiliation":[{"name":"Skin Patients Netherlands (Huidpati\u00ebnten Nederland) Nieuwegein the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Carter","sequence":"additional","affiliation":[{"name":"Biostatistics and Health Informatics King's College London London U.K"},{"name":"Institute of Psychiatry, Psychology and Neuroscience London U.K"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Charland","sequence":"additional","affiliation":[{"name":"Independent Researcher and Consumer Referee Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,3,10]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2010.03751.x"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03167.x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546630701485233"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1506630"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.120625"},{"key":"e_1_2_6_7_1","first-page":"431","article-title":"Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea COnsensus (ROSCO) panel","volume":"17","author":"Tan J","year":"2016","journal-title":"Br J Dermatol"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.08.037"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15173"},{"key":"e_1_2_6_10_1","first-page":"251","article-title":"Rosacea: where are we now?","volume":"3","author":"Bikowski JB","year":"2004","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700"},{"key":"e_1_2_6_12_1","first-page":"CD003262","article-title":"Interventions for rosacea [Protocol]","volume":"12","author":"van Zuuren EJ","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_13_1","unstructured":"HigginsJPT GreenS.Cochrane Handbook for Systematic Reviews of Interventions 5.1.0. Available at:www.cochrane-handbook.org(last accessed 12 September 2018)."},{"key":"e_1_2_6_14_1","unstructured":"Sch\u00fcnemannH BrozekJ GuyattG OxmanA editors.GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations. Updated October 2013. The GRADE Working Group 2013. Available at:https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html(last accessed 5 February 2019)."},{"key":"e_1_2_6_15_1","first-page":"544","article-title":"Treatment of ocular rosacea: comparative study of topical cyclosporine and oral doxycycline","volume":"8","author":"Arman A","year":"2015","journal-title":"Int Journal Ophthalmol"},{"key":"e_1_2_6_16_1","first-page":"290","article-title":"Pivotal trial of the efficacy and safety of oxymetazoline cream 1.0% for the treatment of persistent facial erythema associated with rosacea: findings from the second REVEAL trial","volume":"17","author":"Baumann L","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.3109\/02713683.2015.1122810"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-007651"},{"key":"e_1_2_6_19_1","first-page":"549","article-title":"A pilot, double\u2010blind, placebo\u2010controlled study to assess the efficacy and safety of incobotulinumtoxinA injections in the treatment of rosacea","volume":"16","author":"Dayan S","year":"2017","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.01.023"},{"key":"e_1_2_6_21_1","first-page":"54","article-title":"A phase 3 randomized, double\u2010blind, vehicle\u2010controlled trial of azelaic acid foam 15% in the treatment of papulopustular rosacea","volume":"96","author":"Draelos ZD","year":"2015","journal-title":"Cutis"},{"key":"e_1_2_6_22_1","unstructured":"EUCTR2006\u2010001999\u201020\u2010HU.Assessment of the efficacy and safety of three concentration:1% 0.3% 0.1% of CD5024 cream once daily and CD5024 1% cream twice daily versus its vehicle and versus metronidazole cream (Rozex\u00ae) in patients with papulopustular rosacea over 12\u00a0weeks. Available at:http:\/\/apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2006-001999-20-HU(last accessed 13 September 2018)."},{"key":"e_1_2_6_23_1","unstructured":"EUCTR2006\u2010003707\u201040\u2010DE.Activity of twice daily per os administration of CD06713 at 8\u00a0mg versus its placebo during 4\u00a0weeks treatment in patients with erythemato\u2010telangiectatic rosacea. Available at:http:\/\/apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2006-003707-40-DE(last accessed 13 September 2018)."},{"key":"e_1_2_6_24_1","unstructured":"EUCTR2009\u2010013111\u201035\u2010DE.Effect of CD08514 versus placebo in patients presenting with type 1 rosacea over an 8\u2010week treatment. Available at:http:\/\/apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2009-013111-35-DE(last accessed 13 September 2018)."},{"key":"e_1_2_6_25_1","unstructured":"EUCTR2010\u2010018319\u201013\u2010DE.A double\u2010blind vehicle controlled parallel group study assessing the activity of CD5024 1% cream in subjects with papulopustular rosacea over 12\u00a0weeks treatment. Available at:http:\/\/apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2010-018319-13-DE(last accessed 13 September 2018)."},{"key":"e_1_2_6_26_1","unstructured":"EUCTR2011\u2010002057\u201065\u2010DE.Effect of CD08100\/02 3% gel versus placebo in subjects presenting with erythematotelangiectatic rosacea over a 4\u00a0week treatment period. Available at:http:\/\/apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2011-002057-65-DE(last accessed 13 September 2018)."},{"key":"e_1_2_6_27_1","unstructured":"EUCTR2012\u2010001044\u201022\u2010SE.A multicenter randomized double\u2010blind vehicle\u2010controlled parallel group study to demonstrate the efficacy and assess the safety of CD07805\/47 gel 0.5% applied topically once daily in subjects with moderate to severe facial erythema of rosacea. Available at:http:\/\/apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2012-001044-22-SE(last accessed 13 September 2018)."},{"key":"e_1_2_6_28_1","first-page":"602","article-title":"Dapsone gel in the treatment of papulopustular rosacea: a double\u2010blind randomized clinical trial","volume":"14","author":"Faghihi G","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_29_1","first-page":"418","article-title":"Timolol t\u00f3pico en el tratamiento de ros\u00e1cea eritematotelangiect\u00e1sica. Ensayo cl\u00ednico randomizado doble ciego","volume":"28","author":"Jaque AS","year":"2012","journal-title":"Rev Chilena Dermatol"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000000968"},{"key":"e_1_2_6_31_1","first-page":"97","article-title":"Pivotal trial of the efficacy and safety of oxymetazoline cream 1.0% for the treatment of persistent facial erythema associated with rosacea: findings from the first REVEAL trial","volume":"17","author":"Kircik LH","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.383"},{"key":"e_1_2_6_33_1","first-page":"53","article-title":"Lack of significant anti\u2010inflammatory activity with clindamycin in the treatment of rosacea: results of 2 randomized, vehicle\u2010controlled trials","volume":"100","author":"Martel P","year":"2017","journal-title":"Cutis"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0339-0"},{"key":"e_1_2_6_35_1","unstructured":"NCT00560703.Efficacy and safety of COL\u2010101 for the treatment of blepharitis in patients with facial rosacea. Available at:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00560703(last accessed 13 September 2018)."},{"key":"e_1_2_6_36_1","unstructured":"NCT00617903.A 12\u2010week exploratory multicenter double\u2010blind vehicle\u2010controlled study to investigate the efficacy and safety of topical azelaic acid 15% foam twice daily in patients with papulopustular rosacea. Available at:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00617903(last accessed 13 September 2018)."},{"key":"e_1_2_6_37_1","unstructured":"NCT02147691.Finacea 15% and brimonidine 0.33% gel in the treatment of rosacea \u2013 a pilot study. Available at:https:\/\/clinicaltrials.gov\/show\/NCT02147691(last accessed 13 September 2018)."},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000000888"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13801"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.01.025"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2016.28.5.607"},{"key":"e_1_2_6_42_1","first-page":"1380","article-title":"Long\u2010term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40\u2010week controlled, investigator\u2010blinded trials","volume":"13","author":"Stein Gold L","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_43_1","first-page":"909","article-title":"Treatment of rosacea with concomitant use of topical ivermectin 1% cream and brimonidine 0.33% gel: a randomized, vehicle\u2010controlled study","volume":"16","author":"Stein Gold L","year":"2017","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15155"},{"key":"e_1_2_6_45_1","first-page":"413","article-title":"The efficacy of hydroxychloroquine combined with 595\u00a0nm pulsed dye laser for acne rosacea","volume":"46","author":"Zhang L","year":"2017","journal-title":"J Clin Dermatol"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsi.2015.04.012"},{"issue":"1","key":"e_1_2_6_47_1","first-page":"AB11","article-title":"The role of long\u2010term doxycycline 40\u00a0mg modified release in the prevention of disease relapse in moderate to severe rosacea","volume":"72","author":"Berlin JM","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_6_48_1","unstructured":"EUCTR2011\u2010002058\u201030\u2010DE.Effect of CD08100\/02 3% gel versus placebo gel in subjects presenting with papulopustular rosacea over a 6\u2010week treatment period. Available at:http:\/\/apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2011-002058-30-DE(last accessed 13 September 2018)."},{"key":"e_1_2_6_49_1","unstructured":"EUCTR2013\u2010005083\u201026\u2010DE.Effect of CD07805\/47 gel in subjects presenting with flushing related to erythematotelangiectatic or papulopustular rosacea \u2013 effect of CD07805\/47 gel in rosacea flushing. Available at:http:\/\/apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2013-005083-26-DE(last accessed 13 September 2018)."},{"issue":"1","key":"e_1_2_6_50_1","first-page":"105","article-title":"Comparative split study on vascular lesions in Korean patients with conventional pulsed dye laser and IRIS laser","volume":"41","author":"Han G","year":"2014","journal-title":"J Dermatol"},{"key":"e_1_2_6_51_1","first-page":"1481","article-title":"Oral azithromycin versus doxycyclin for the treatment of moderate to severe meibomian gland dysfunction (MGD): a randomized prospective non\u2010inferiority study","volume":"55","author":"Heitz A","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_6_52_1","first-page":"213","article-title":"Clinical pharmacokinetics of oxymetazoline cream following topical facial administration for the treatment of erythema associated with rosacea","volume":"17","author":"Kuang AW","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_53_1","unstructured":"NCT00697541.A phase II single\u2010center two\u2010way crossover relative systemic bioavailability study of Col\u2010118 administered topically as a 0.18% facial gel and brimonidine ophthalmic solution 0.2% administered to the eye in subjects with moderate to severe erythematous rosacea. Available at:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00697541(last accessed 13 September 2018)."},{"key":"e_1_2_6_54_1","unstructured":"NCT01579084.Safety and tolerability of AGN\u2010199201 in patients with erythema associated with rosacea. Available at:https:\/\/clinicaltrials.gov\/show\/NCT01579084(last accessed 13 September 2018)."},{"key":"e_1_2_6_55_1","unstructured":"NCT01735201.AGN\u2010199201 for the treatment of erythema with rosacea. Available at:https:\/\/clinicaltrials.gov\/show\/NCT01735201(last accessed 13 September 2018)."},{"key":"e_1_2_6_56_1","unstructured":"NCT02300129.Effect of CD07805\/47 gel in subjects presenting with flushing related to erythematotelangiectatic or papulopustular rosacea. Available at:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02300129(last accessed 13 September 2018)."},{"key":"e_1_2_6_57_1","unstructured":"NCT03035955.The effect of azelaic acid (Finacea gel 15%) on Demodex folliculorum counts in adult subjects with mild to moderate papulopustular rosacea. Available at:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03035955(last accessed 13 September 2018)."},{"key":"e_1_2_6_58_1","first-page":"426","article-title":"Prospective, randomized, controlled split\u2010face study of the 532\u00a0nm KTP laser and 595\u00a0nm pulsed dye laser for the treatment of erythematotelangiectatic rosacea and papulopustular rosacea","volume":"48","author":"Waibel J","year":"2016","journal-title":"Lasers Surg Med"},{"key":"e_1_2_6_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12881"},{"key":"e_1_2_6_60_1","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2340\/0001555564358359","article-title":"Topical treatment with sulfur 10 per cent for rosacea","volume":"64","author":"Blom I","year":"1984","journal-title":"Acta Derm Venereol"},{"issue":"25","key":"e_1_2_6_61_1","first-page":"43","article-title":"Skin barrier function assessment by in\u00a0vivo confocal microscopy and other non\u2010invasive optical measurements on patients suffering from rosacea to evaluate the efficacy of a post\u2010laser serum","volume":"45","author":"Buendia\u2010Bordera G","year":"2013","journal-title":"Lasers Surg Med"},{"key":"e_1_2_6_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1473-2165.2006.00219.x"},{"issue":"1","key":"e_1_2_6_63_1","first-page":"AB82","article-title":"Facial foundation with niacinamide and N\u2010acetylglucosamine improves skin condition in women with sensitive skin","volume":"60","author":"Draelos Z","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_6_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.12061"},{"key":"e_1_2_6_65_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1994.01690030051008"},{"key":"e_1_2_6_66_1","first-page":"129","article-title":"Double\u2010blind study versus excipient of 0.75% metronidazole gel in the treatment of rosacea","volume":"120","author":"Espagne E","year":"1993","journal-title":"Ann Dermatol Venereol"},{"issue":"23","key":"e_1_2_6_67_1","first-page":"968","article-title":"Combination 15% azelaic acid gel and intense pulse light therapy for mild to moderate rosacea","volume":"43","author":"Fabi S","year":"2011","journal-title":"Lasers Surg Med"},{"key":"e_1_2_6_68_1","first-page":"S145","article-title":"Metronidazole 0.75% gel and lotion are both effective in the treatment of rosacea","volume":"12","author":"Guillet B","year":"1999","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"e_1_2_6_69_1","first-page":"AB9","article-title":"Multicenter, randomized, double\u2010blind, placebo\u2010controlled evaluation of rosacea related inflammatory biomarkers in papulopustular rosacea adults treated with doxycycline 40\u00a0mg modified release","volume":"70","author":"Huang EY","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_6_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(98)70337-8"},{"issue":"1","key":"e_1_2_6_71_1","first-page":"AB43","article-title":"Evaluation of the safety and effectiveness of microfocused ultrasound with visualization (MFU\u2010V) for the treatment of erythematotelangiectatic rosacea","volume":"70","author":"Lupin M","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_6_72_1","unstructured":"NCT00249782.A phase II randomized partial\u2010blind parallel\u2010group active\u2010 and vehicle\u2010controlled multicenter study of the safety and efficacy of ACZONE\u2122 (dapsone) gel 5% in subjects with papulopustular rosacea. Available at:https:\/\/clinicaltrials.gov\/ct\/show\/NCT00249782(last accessed 19 July 2014)."},{"key":"e_1_2_6_73_1","first-page":"AB64","article-title":"A double\u2010blind, placebo\u2010controlled study of a natural anti\u2010inflammatory for treatment of rosacea","volume":"54","author":"Rehmus W","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"e_1_2_6_74_1","first-page":"17","article-title":"Efficacy and safety of subantimicrobial\u2010dose doxycycline for the treatment of rosacea","volume":"52","author":"Thiboutot D","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_6_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.1997.tb00469.x"},{"key":"e_1_2_6_76_1","first-page":"729","article-title":"Treatment of rosacea. Clonidine (0.075\u00a0mg per day) versus placebo (initial results)","volume":"124","author":"Van Landuyt H","year":"1997","journal-title":"Ann Dermatol Venereol"},{"key":"e_1_2_6_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(89)70022-0"},{"key":"e_1_2_6_78_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1993.tb00974.x"},{"key":"e_1_2_6_79_1","article-title":"Efficacy of cyclosporine a for the treatment of ocular rosacea","volume":"46","author":"Wittpenn JR","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"23","key":"e_1_2_6_80_1","first-page":"918","article-title":"Combination therapy for the treatment of erythematotelangiectatic rosacea","volume":"43","author":"Yoo J","year":"2011","journal-title":"Lasers Surg Med"},{"key":"e_1_2_6_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2008.03445.x"},{"key":"e_1_2_6_82_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.135.6.659"},{"key":"e_1_2_6_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(96)30412-0"},{"issue":"3","key":"e_1_2_6_84_1","doi-asserted-by":"crossref","first-page":"P10","DOI":"10.1016\/j.jaad.2004.10.055","article-title":"A multi\u2010center, investigator\u2010blind clinical trial to assess the safety and efficacy of metronidazole gel 1% as compared to metronidazole gel vehicle and metronidazole cream 1% in the treatment of rosacea","volume":"52","author":"Beutner K","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_6_85_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03259203"},{"key":"e_1_2_6_86_1","first-page":"187","article-title":"Metronidazole (Elyzol) 1% cream vs. placebo cream in the treatment of rosacea","volume":"26","author":"Bjerke JR","year":"1989","journal-title":"Clin Trials J"},{"key":"e_1_2_6_87_1","doi-asserted-by":"publisher","DOI":"10.1080\/000155599750009906"},{"key":"e_1_2_6_88_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1987.01660290077020"},{"key":"e_1_2_6_89_1","first-page":"44","article-title":"A double\u2010blind, multicenter clinical trial comparing efficacy of once\u2010daily metronidazole 1 percent cream to vehicle in patients with rosacea","volume":"61","author":"Breneman DL","year":"1998","journal-title":"Cutis"},{"key":"e_1_2_6_90_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2004.02283.x"},{"key":"e_1_2_6_91_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546639309082150"},{"key":"e_1_2_6_92_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.6.679"},{"key":"e_1_2_6_93_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.116219"},{"key":"e_1_2_6_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.11.021"},{"key":"e_1_2_6_95_1","first-page":"573","article-title":"Comparison of anti\u2010inflammatory dose doxycycline versus doxycycline 100\u00a0mg in the treatment of rosacea","volume":"7","author":"Del Rosso JQ","year":"2008","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_96_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2005.31735"},{"key":"e_1_2_6_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0926-9959(98)95615-X"},{"key":"e_1_2_6_98_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.11.1444"},{"key":"e_1_2_6_99_1","first-page":"641","article-title":"Combined effect of anti\u2010inflammatory dose doxycycline (40\u2010mg doxycycline, usp monohydrate controlled\u2010release capsules) and metronidazole topical gel 1% in the treatment of rosacea","volume":"6","author":"Fowler JF","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_100_1","first-page":"687","article-title":"Rilmenidine in rosacea: a double blind study versus placebo","volume":"124","author":"Grosshans E","year":"1997","journal-title":"Ann Dermatol Venereol"},{"key":"e_1_2_6_101_1","first-page":"702","article-title":"Treatment of facial telangiectasia using a dual\u2010wavelength laser system (595 and 1,064\u00a0nm): a randomized controlled trial with blinded response evaluation","volume":"34","author":"Karsai S","year":"2008","journal-title":"Dermatol Surg"},{"key":"e_1_2_6_102_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2009.03427.x"},{"issue":"32","key":"e_1_2_6_103_1","first-page":"S143","article-title":"Dark sulfonated shale oil versus placebo in the systemic treatment of rosacea","volume":"12","author":"Koch R","year":"1999","journal-title":"J Eur Acad Dermatol Venerol"},{"key":"e_1_2_6_104_1","doi-asserted-by":"publisher","DOI":"10.1159\/000065849"},{"key":"e_1_2_6_105_1","first-page":"183","article-title":"The comparative efficacy of sodium sulfacetamide 10%\/sulfur 5% (Sulfacet\u2010R) lotion and metronidazole 0.75% (Metrogel) in the treatment of rosacea","volume":"3","author":"Lebwohl MG","year":"1995","journal-title":"J Geriatr Dermatol"},{"key":"e_1_2_6_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70085-X"},{"key":"e_1_2_6_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(71)90376-X"},{"key":"e_1_2_6_108_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546639109092728"},{"key":"e_1_2_6_109_1","first-page":"185","article-title":"Topical treatment of acne rosacea with benzoyl peroxide acetone gel","volume":"32","author":"Montes LF","year":"1983","journal-title":"Cutis"},{"key":"e_1_2_6_110_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2008.02940.x"},{"key":"e_1_2_6_111_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2009.01156.x"},{"key":"e_1_2_6_112_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1983.tb03972.x"},{"key":"e_1_2_6_113_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1983.tb03993.x"},{"key":"e_1_2_6_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(76)92160-7"},{"key":"e_1_2_6_115_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2005.01248.x"},{"key":"e_1_2_6_116_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1980.tb06558.x"},{"key":"e_1_2_6_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.04.069"},{"key":"e_1_2_6_118_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546639709160276"},{"key":"e_1_2_6_119_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03259568"},{"key":"e_1_2_6_120_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-009-0037-2"},{"key":"e_1_2_6_121_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2006.02944.x"},{"key":"e_1_2_6_122_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1966.tb12168.x"},{"key":"e_1_2_6_123_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10227-001-0144-4"},{"key":"e_1_2_6_124_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.308"},{"key":"e_1_2_6_125_1","first-page":"541","article-title":"Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea","volume":"7","author":"Thiboutot DM","year":"2008","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_126_1","first-page":"639","article-title":"A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance therapy","volume":"8","author":"Thiboutot DM","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_127_1","first-page":"357","article-title":"Combination sodium sulfacetamide 10% and sulfur 5% cream with sunscreens versus metronidazole 0.75% cream for rosacea","volume":"75","author":"Torok HM","year":"2005","journal-title":"Cutis"},{"key":"e_1_2_6_128_1","first-page":"209","article-title":"Topical metronidazole in the treatment of rosacea","volume":"38","author":"Veien NK","year":"1986","journal-title":"Cutis"},{"key":"e_1_2_6_129_1","first-page":"472","article-title":"Comparative study of topical erythromycin and topical metronidazole in the treatment of rosacea","volume":"9","author":"Verea Hernando M","year":"1992","journal-title":"Farm Clin"},{"key":"e_1_2_6_130_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07669.x"},{"issue":"4","key":"e_1_2_6_131_1","first-page":"3","article-title":"Efficacy and safety of once\u2010daily metronidazole 1% gel compared with twice\u2010daily azelaic acid 15% gel in the treatment of rosacea","volume":"77","author":"Wolf JE","year":"2006","journal-title":"Cutis"},{"key":"e_1_2_6_132_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.04.015"},{"key":"e_1_2_6_133_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2011.05353.x"},{"key":"e_1_2_6_134_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1473-2165.2011.00598.x"},{"key":"e_1_2_6_135_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12552"},{"key":"e_1_2_6_136_1","first-page":"333","article-title":"A randomized, double\u2010blind, placebo\u2010controlled, pilot study to assess the efficacy and safety of clindamycin 1.2% and tretinoin 0.025% combination gel for the treatment of acne rosacea over 12\u00a0weeks","volume":"11","author":"Chang AL","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_137_1","first-page":"607","article-title":"Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40\u00a0mg versus metronidazole gel 1% plus oral doxycycline 40\u00a0mg in mild\u2010to\u2010moderate papulopustular rosacea","volume":"9","author":"Del Rosso JQ","year":"2010","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_138_1","first-page":"306","article-title":"Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double\u2010blind, vehicle\u2010controlled study","volume":"92","author":"Draelos ZD","year":"2013","journal-title":"Cutis"},{"key":"e_1_2_6_139_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10716.x"},{"key":"e_1_2_6_140_1","first-page":"650","article-title":"Efficacy and safety of once\u2010daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double\u2010blind, and vehicle\u2010controlled pivotal studies","volume":"12","author":"Fowler J","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_141_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2010.07345_supp.x"},{"key":"e_1_2_6_142_1","first-page":"308","article-title":"Clinical research of topical tacrolimus ointment combined with 585\u00a0nm pulsed dye laser in the treatment of rosacea","volume":"41","author":"Huang YE","year":"2012","journal-title":"J Clinical Dermatol"},{"key":"e_1_2_6_143_1","first-page":"292","article-title":"Efficacy of extended\u2010release 45\u00a0mg oral minocycline and extended\u2010release 45\u00a0mg oral minocycline plus 15% azelaic acid in the treatment of acne rosacea","volume":"12","author":"Jackson JM","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_144_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.03.1059"},{"key":"e_1_2_6_145_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2010.00999.x"},{"key":"e_1_2_6_146_1","first-page":"1179","article-title":"Efficacy of a novel rosacea treatment system: an investigator\u2010blind, randomized, parallel\u2010group study","volume":"10","author":"Leyden JJ","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_147_1","first-page":"685","article-title":"Randomized, phase 2, dose\u2010ranging study in the treatment of rosacea with encapsulated benzoyl peroxide gel","volume":"13","author":"Leyden JJ","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_148_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12520"},{"key":"e_1_2_6_149_1","unstructured":"NCT01426269.Evaluation of relapse efficacy and safety of long\u2010term treatment with Oracea\u00aecapsules compared to placebo after an initial 12\u00a0week treatment regimen with Oracea\u00aeand MetroGel\u00ae1% in adults with rosacea. Available at:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01426269(last accessed 21 July 2014)."},{"key":"e_1_2_6_150_1","unstructured":"NCT01449591.A proof of concept (PoC) study to evaluate the safety tolerability and efficacy of 12\u00a0week administration of BFH772 ointment in rosacea patients. Available at:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01449591(last accessed 19 July 2014)."},{"key":"e_1_2_6_151_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13305"},{"key":"e_1_2_6_152_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03357.x"},{"key":"e_1_2_6_153_1","first-page":"126","article-title":"A comparative, double\u2010blind study about efficacy and safety of crotamiton vs benzyl benzoate in the treatment of rosacea with demodecidosis","volume":"47","author":"Rodr\u00edguez Acar M","year":"2003","journal-title":"Dermatol Rev Mex"},{"key":"e_1_2_6_154_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2012.11.022"},{"key":"e_1_2_6_155_1","first-page":"920","article-title":"Management of rosacea\u2010prone skin: evaluation of a skincare product containing Ambophenol, Neurosensine, and La Roche\u2010Posay Thermal spring water as monotherapy or adjunctive therapy","volume":"12","author":"Seit\u00e9 S","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_156_1","first-page":"316","article-title":"Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double\u2010blind, vehicle\u2010controlled pivotal studies","volume":"13","author":"Stein L","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_157_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13408"},{"key":"e_1_2_6_158_1","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.60.583"},{"key":"e_1_2_6_159_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.472"},{"key":"e_1_2_6_160_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08832.x"},{"key":"e_1_2_6_161_1","doi-asserted-by":"publisher","DOI":"10.1159\/000365390"},{"key":"e_1_2_6_162_1","first-page":"CD003262","article-title":"Interventions for rosacea","volume":"4","author":"van Zuuren EJ","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_163_1","doi-asserted-by":"publisher","DOI":"10.1177\/1203475416650427"},{"key":"e_1_2_6_164_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14349"},{"key":"e_1_2_6_165_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-015-0150-8"},{"key":"e_1_2_6_166_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-018-0249-y"},{"key":"e_1_2_6_167_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-016-2819-8"},{"key":"e_1_2_6_168_1","first-page":"CD003262","article-title":"Interventions for rosacea","volume":"3","author":"van Zuuren EJ","year":"2011","journal-title":"Cochrane Database Syst Rev"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.17590","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjd.17590","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjd.17590","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjd.17590","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T13:00:13Z","timestamp":1694523613000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/181\/1\/65\/6747190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,10]]},"references-count":167,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1111\/bjd.17590"],"URL":"https:\/\/doi.org\/10.1111\/bjd.17590","archive":["Portico"],"relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,10]]},"assertion":[{"value":"2018-12-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}